These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants. Roeffen W; Theisen M; van de Vegte-Bolmer M; van Gemert G; Arens T; Andersen G; Christiansen M; Sevargave L; Singh SK; Kaviraj S; Sauerwein R Malar J; 2015 Nov; 14():443. PubMed ID: 26552428 [TBL] [Abstract][Full Text] [Related]
65. Evaluation of two sexual-stage antigens as bivalent transmission-blocking vaccines in rodent malaria. Yang F; Liu F; Yu X; Zheng W; Wu Y; Qiu Y; Jin Y; Cui L; Cao Y Parasit Vectors; 2021 May; 14(1):241. PubMed ID: 33962671 [TBL] [Abstract][Full Text] [Related]
66. A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages. Theisen M; Roeffen W; Singh SK; Andersen G; Amoah L; van de Vegte-Bolmer M; Arens T; Tiendrebeogo RW; Jones S; Bousema T; Adu B; Dziegiel MH; Christiansen M; Sauerwein R Vaccine; 2014 May; 32(22):2623-30. PubMed ID: 24662702 [TBL] [Abstract][Full Text] [Related]
67. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Kubler-Kielb J; Majadly F; Wu Y; Narum DL; Guo C; Miller LH; Shiloach J; Robbins JB; Schneerson R Proc Natl Acad Sci U S A; 2007 Jan; 104(1):293-8. PubMed ID: 17190797 [TBL] [Abstract][Full Text] [Related]
68. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium. Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765 [TBL] [Abstract][Full Text] [Related]
69. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles. Lalitha PV; Biswas S; Pillai CR; Saxena RK Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786 [TBL] [Abstract][Full Text] [Related]
70. TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25. Thompson EA; Ols S; Miura K; Rausch K; Narum DL; Spångberg M; Juraska M; Wille-Reece U; Weiner A; Howard RF; Long CA; Duffy PE; Johnston L; O'Neil CP; Loré K JCI Insight; 2018 May; 3(10):. PubMed ID: 29769448 [TBL] [Abstract][Full Text] [Related]
71. Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials. Zou L; Miles AP; Wang J; Stowers AW Vaccine; 2003 Apr; 21(15):1650-7. PubMed ID: 12639486 [TBL] [Abstract][Full Text] [Related]
73. Evaluation of a new fusion antigen, cd loop and HAP2-GCS1 domain (cd-HAP) of Plasmodium falciparum Generative Cell Specific 1 antigen formulated with various adjuvants, as a transmission blocking vaccine. Pourhashem Z; Nourani L; Sani JJ; Yousefi H; Pirahmadi S; Sabouri M; Raz A; Djadid ND; Zakeri S; Mehrizi AA Malar J; 2023 Dec; 22(1):374. PubMed ID: 38071314 [TBL] [Abstract][Full Text] [Related]
74. Antibody responses to two new Lactococcus lactis-produced recombinant Pfs48/45 and Pfs230 proteins increase with age in malaria patients living in the Central Region of Ghana. Acquah FK; Obboh EK; Asare K; Boampong JN; Nuvor SV; Singh SK; Theisen M; Williamson KC; Amoah LE Malar J; 2017 Aug; 16(1):306. PubMed ID: 28764709 [TBL] [Abstract][Full Text] [Related]
75. Immunological properties of recombinant proteins of the transmission blocking vaccine candidate, Pfs48/45, of the human malaria parasite Plasmodium falciparum produced in Escherichia coli. Milek RL; Roeffen WF; Kocken CH; Jansen J; Kaan AM; Eling WM; Sauerwein RW; Konings RN Parasite Immunol; 1998 Aug; 20(8):377-85. PubMed ID: 9767603 [TBL] [Abstract][Full Text] [Related]
76. Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies. Lobo CA; Dhar R; Kumar N Infect Immun; 1999 Apr; 67(4):1688-93. PubMed ID: 10085005 [TBL] [Abstract][Full Text] [Related]
77. Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25. McLeod B; Miura K; Scally SW; Bosch A; Nguyen N; Shin H; Kim D; Volkmuth W; Rämisch S; Chichester JA; Streatfield S; Woods C; Schief WR; Emerling D; King CR; Julien JP Nat Commun; 2019 Sep; 10(1):4328. PubMed ID: 31551421 [TBL] [Abstract][Full Text] [Related]
78. Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A. Brando C; Ware LA; Freyberger H; Kathcart A; Barbosa A; Cayphas S; Demoitie MA; Mettens P; Heppner DG; Lanar DE Infect Immun; 2007 Feb; 75(2):838-45. PubMed ID: 17101665 [TBL] [Abstract][Full Text] [Related]
79. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle. Shimp RL; Rowe C; Reiter K; Chen B; Nguyen V; Aebig J; Rausch KM; Kumar K; Wu Y; Jin AJ; Jones DS; Narum DL Vaccine; 2013 Jun; 31(28):2954-62. PubMed ID: 23623858 [TBL] [Abstract][Full Text] [Related]